Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
60.81
-7.98 (-11.60%)
After Hours: 61.00 +0.19 (0.31%)
May 3, 5:30PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 60.07 - 66.99
52 week 51.51 - 140.00
Open 66.80
Vol / Avg. 1.83M/796,497.00
Mkt cap 5.33B
P/E     -
Div/yield     -
EPS -4.03
Shares 85.50M
Beta 2.47
Inst. own 79%
May 12, 2016
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference - 1:00PM EDT - Add to calendar
May 10, 2016
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting - 8:00AM EDT - Add to calendar
May 4, 2016
Alnylam Pharmaceuticals Inc at Deutsche Bank Health Care Conference - 8:40AM EDT - Add to calendar
May 2, 2016
Q1 2016 Alnylam Pharmaceuticals Inc Earnings Call - Webcast
May 2, 2016
Q1 2016 Alnylam Pharmaceuticals Inc Earnings Release
Apr 29, 2016
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Apr 20, 2016
Alnylam Pharmaceuticals Inc Conference Call to discuss 18-Month data from its ongoing Phase 2 open-label extension
Apr 13, 2016
Alnylam Pharmaceuticals Inc at Needham Healthcare Conference
Mar 15, 2016
Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference
Mar 7, 2016
Alnylam Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1401.96% -705.83%
Operating margin -1498.00% -720.27%
EBITD margin - -673.91%
Return on average assets -30.56% -23.52%
Return on average equity -33.66% -26.36%
Employees 369 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company’s pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President - General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
David-Alexandre Gros M.D. Senior Vice President, Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 41
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 62
Bio & Compensation  - Reuters
Marsha H. Fanucci Independent Director
Age: 62
Bio & Compensation  - Reuters